Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Marinus Pharma CS (MRNS)

Marinus Pharma CS (MRNS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 97,783
  • Shares Outstanding, K 54,934
  • Annual Sales, $ 30,990 K
  • Annual Income, $ -141,410 K
  • 60-Month Beta 1.14
  • Price/Sales 3.08
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade MRNS with:

Options Overview Details

View History
  • Implied Volatility 240.97% ( +130.95%)
  • Historical Volatility 76.86%
  • IV Percentile 92%
  • IV Rank 36.71%
  • IV High 618.48% on 09/06/24
  • IV Low 22.02% on 07/12/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 336
  • Volume Avg (30-Day) 380
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 11,682
  • Open Int (30-Day) 8,072

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.45
  • Number of Estimates 6
  • High Estimate -0.40
  • Low Estimate -0.50
  • Prior Year -0.61
  • Growth Rate Est. (year over year) +26.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3400 +32.84%
on 09/06/24
1.9700 -9.64%
on 09/24/24
+0.3600 (+25.35%)
since 09/04/24
3-Month
1.0500 +69.52%
on 08/14/24
1.9700 -9.64%
on 09/24/24
+0.5700 (+47.11%)
since 07/03/24
52-Week
1.0500 +69.52%
on 08/14/24
11.2600 -84.19%
on 01/08/24
-5.8300 (-76.61%)
since 10/04/23

Most Recent Stories

More News
Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?

Marinus is an under $2 biotech stock with Wall Street analysts price targets ranging from $2 to $13. Its upcoming trial results have big implications.

MRNS : 1.7800 (+2.89%)
Marinus Pharmaceuticals: Q2 Earnings Snapshot

Marinus Pharmaceuticals: Q2 Earnings Snapshot

MRNS : 1.7800 (+2.89%)
Marinus Pharmaceuticals: Q1 Earnings Snapshot

Marinus Pharmaceuticals: Q1 Earnings Snapshot

MRNS : 1.7800 (+2.89%)
Marinus Pharmaceuticals: Q4 Earnings Snapshot

Marinus Pharmaceuticals: Q4 Earnings Snapshot

MRNS : 1.7800 (+2.89%)
Marinus Pharmaceuticals: Q3 Earnings Snapshot

Marinus Pharmaceuticals: Q3 Earnings Snapshot

MRNS : 1.7800 (+2.89%)
Marinus Pharmaceuticals: Q2 Earnings Snapshot

Marinus Pharmaceuticals: Q2 Earnings Snapshot

MRNS : 1.7800 (+2.89%)
Marinus Pharmaceuticals: Q1 Earnings Snapshot

Marinus Pharmaceuticals: Q1 Earnings Snapshot

MRNS : 1.7800 (+2.89%)
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present...

MRNS : 1.7800 (+2.89%)
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 11, 2023

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial...

MRNS : 1.7800 (+2.89%)
Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Marvin H....

MRNS : 1.7800 (+2.89%)

Business Summary

Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical...

See More

Key Turning Points

3rd Resistance Point 1.9400
2nd Resistance Point 1.8800
1st Resistance Point 1.8300
Last Price 1.7800
1st Support Level 1.7200
2nd Support Level 1.6600
3rd Support Level 1.6100

See More

52-Week High 11.2600
Fibonacci 61.8% 7.3598
Fibonacci 50% 6.1550
Fibonacci 38.2% 4.9502
Last Price 1.7800
52-Week Low 1.0500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar